Berotralstat

Berotralstat (BCX7353) is an orally active plasma kallikrein inhibitor. Berotralstat can reduce brain edema and is being studied for glioblastoma and hereditary angioedema[1][2].

Product Specifications

CAS Number

[1809010-50-1]

Product Name Alternative

BCX7353

UNSPSC

12352005

Hazard Statement

H315, H319, H320

Target

Kallikrein

Type

Reference compound

Related Pathways

Immunology/Inflammation

Field of Research

Cancer; Cardiovascular Disease

Assay Protocol

https://www.medchemexpress.com/berotralstat.html

Purity

99.70

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

O=C(C1=CC(C(F)(F)F)=NN1C2=CC(CN)=CC=C2)NC3=CC([C@@H](C4=CC(C#N)=CC=C4)NCC5CC5)=CC=C3F

Molecular Formula

C30H26F4N6O

Molecular Weight

562.56

Precautions

H315, H319, H320

References & Citations

[1]Zuraw B, et al. Oral once-daily berotralstat for the prevention of hereditary angioedema attacks: A randomized, double-blind, placebo-controlled phase 3 trial [published online ahead of print, 2020 Oct 21]. J Allergy Clin Immunol. 2020; S0091-6749 (20) 31484-6.|[2]Richard E. Kast, et al. Reducing Brain Edema Using Berotralstat, an Inhibitor of Bradykinin, Repurposed as Treatment Adjunct in Glioblastoma. Neuroglia. 2024, 5 (3), 223-233.|[3]Perego F, et al., Current and emerging biologics for the treatment of hereditary angioedema. Expert Opin Biol Ther. 2019 Jun;19 (6) :517-526.|[4]Wan J, et al., Plasma kallikrein supports FXII-independent thrombin generation in mouse whole blood. Blood Adv. 2024 Jun 25;8 (12) :3045-3057.